NCT03463460 2025-08-24
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
Ohio State University Comprehensive Cancer Center
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Seoul National University Hospital